CJC-1295 (no DAC) and Ipamorelin is a research peptide blend combining two mechanistically distinct secretagogues that act synergistically on the growth hormone axis. CJC-1295 (Mod GRF 1–29) targets GHRH receptors, stimulating cAMP/PKA-mediated GH synthesis, while Ipamorelin binds the ghrelin receptor (GHS-R1a), activating Gq/11-linked calcium signaling pathways. Together, they serve as a model for studying peptide-induced GH pulsatility, receptor cross-talk, and hypothalamic–pituitary regulation in controlled experimental systems.
For research use only. Not for human consumption.
References:
Bowers CY et al., Endocrinology, 1990 126(2):1165–1171
Teichman SL et al., J Clin Endocrinol Metab, 2006 91(2):479–487
Kojima M et al., Nature, 1999 402(6762):656–660
